Why Novo Nordisk (NVO) is a Top Value Stock for the Long-Term

Zacks Investment Research highlights Novo Nordisk (NVO) as a compelling long-term value stock, assigning it a Zacks Rank #3 (Hold) but noting strong B-rated VGM and Value Style Scores. The company's attractive forward P/E of 17.62, coupled with recent upward revisions to its fiscal 2025 earnings estimates by analysts, positions NVO as a noteworthy consideration for investors seeking value, despite its 'Hold' rank, by leveraging Zacks' integrated methodology.

Analysis

Novo Nordisk (NVO) is presented as a notable value stock for long-term consideration, despite carrying a neutral Zacks Rank of #3 (Hold). The investment thesis is supported by strong underlying metrics, including a B-grade for both its overall VGM (Value, Growth, Momentum) Score and its specific Value Style Score. The company's valuation is highlighted as attractive with a forward P/E ratio of 17.62. Further bolstering the positive outlook for fiscal 2025, two analysts have revised their earnings estimates upward within the last 60 days, resulting in a $0.04 increase in the Zacks Consensus Estimate to $3.93 per share. However, a key tempering data point is the company’s average earnings surprise of 0%, indicating a consistent history of meeting, rather than exceeding, earnings expectations, which aligns with its current 'Hold' rating.

Key Decisions for Investors

• Value-oriented investors should consider NVO's attractive valuation, evidenced by a forward P/E of 17.62 and a B-rated Value Score, as a potential basis for a long-term position.
• Given the #3 (Hold) rank and a historical 0% average earnings surprise, investors should not anticipate significant near-term alpha from earnings beats but rather view the stock based on its fundamental value and market position.
• The upward revisions to fiscal 2025 earnings estimates represent a key forward-looking catalyst; investors should monitor future analyst estimate trends for confirmation of an improving long-term outlook.